C4 <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces $125 Million Underwritten Offering with Potential to Raise Up to $349.7 Million Through Stock and Warrant Sales
C4 Therapeutics Inc. (C4T) has announced the pricing of an underwritten offering, raising $125 million in upfront proceeds through the sale of 21,895,000 shares of its common stock and pre-funded warrants to purchase an additional 28,713,500 shares. Each share and pre-funded warrant is accompanied by a Class A Warrant and a Class B Warrant, each exercisable at $2.22 per share. The offering was led by RA Capital Management with participation from existing shareholders including OrbiMed, Soleus Capital, Lynx1 Capital Management, and Bain Capital Life Sciences. If all accompanying warrants are exercised, C4T could receive up to $349.7 million in total gross proceeds. The funds are intended to support ongoing and planned clinical trials of cemsidomide, other R&D activities, and general corporate purposes. Jefferies, TD Cowen, and Evercore ISI are acting as book-running managers for the offering.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9546776-en) on October 16, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.